Elacestrant Impresses in EMERALD Trial of Breast Cancer

LANDMARK TRIALS IN BREAST CANCER

Frontiers Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US payer perspective

Promising Phase III Results in HR+/HER2- Breast Cancer

EMERALD: Elacestrant in Relapsed/Refractory HR+/HER2- mBC

Experts Discuss Clinical Highlights from SABCS 2021

ASCO Breast Cancer Session 2021: Panel Discussion

How are people with liver mets doing? - Page 654 — Breastcancer.org

Pipeline Report 2022: Patient experience takes center stage

Ahmed Rabie on LinkedIn: #menarini #stemline #orserdu #elzonris #patientcare #teamwork #winning…

Lorenzo Gerratana on X: First results of the EMERALD trial: single agent # elacestrant is a promising new endocrine option, #biomarkers are needed for a real #personalized treatment there is a rapidly progressive

Experts Discuss Clinical Highlights from SABCS 2021